| Website | onyvax.com |
| Category | BioTech |
| Employees |
| TOTAL | $14.9M |
| FUNDING TOTAL | $14.9M |
| Series C, 5/06 3i Group SR One Merlin Biosciences MB Venture Capital Fund Alta Berkeley Venture Partners | £8M |
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax’s products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.
